Literature DB >> 20080915

Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia.

Frederick Wolfe1, Kaleb Michaud, Tracy Li, Robert S Katz.   

Abstract

OBJECTIVES: To describe and compare the prevalence of lifetime and current self-reported comorbidity and associated quality of life in 4 rheumatic diseases, and to investigate comorbid conditions in light of the overlap between the index condition and comorbid conditions (CC), and in the context of symptom-type diagnoses.
METHODS: We studied comorbidity in 11,704 patients with fibromyalgia (FM), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and noninflammatory rheumatic disorders (NIRD). Patients completed semiannual self-reports relating to 22 present and past illnesses and completed the EuroQol (EQ-5D) utility index.
RESULTS: CC were most common in FM, followed by SLE. FM comorbidity was dominated by depression, mental illness, and symptom-type comorbidity (e.g., gastrointestinal and genitourinary disorders). In SLE, there were substantial increases in hypertension, depression, cataract, fractures, and cardiovascular and cerebrovascular, neurologic, lung, gall bladder and endocrine disorders compared with RA. Any current CC reduced the EQ-5D utility by 0.08 to 0.16 units. The lowest EQ-5D score was noted for current psychiatric illness (0.55) and current depression (0.60).
CONCLUSION: Four patterns of comorbidity emerged: that associated with aging; that associated with aging but enhanced by the index condition, as in SLE and cardiovascular disease; comorbidity that is part of the symptoms complex of the index condition; and CC that represent lifetime traits or manifestations of the underlying illness. Depression was the most strongly associated correlate of EQ-5D quality of life, and current depression was present in about 15% of patients with RA or NIRD and 34% to 39% of those with SLE and FM.

Entities:  

Mesh:

Year:  2010        PMID: 20080915     DOI: 10.3899/jrheum.090781

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  44 in total

1.  Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients.

Authors:  Kaleb Michaud; Gene Wallenstein; Frederick Wolfe
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-11-15       Impact factor: 4.794

Review 2.  Worldwide epidemiology of fibromyalgia.

Authors:  Luiz Paulo Queiroz
Journal:  Curr Pain Headache Rep       Date:  2013-08

3.  Differential Association of Psychosocial Comorbidities With Subclinical Atherosclerosis in Rheumatoid Arthritis.

Authors:  Ying L Liu; Moyses Szklo; Karina W Davidson; Joan M Bathon; Jon T Giles
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-10       Impact factor: 4.794

4.  Predictors of longterm changes in body mass index in rheumatoid arthritis.

Authors:  Joshua F Baker; Grant W Cannon; Said Ibrahim; Candace Haroldsen; Liron Caplan; Ted R Mikuls
Journal:  J Rheumatol       Date:  2015-04-01       Impact factor: 4.666

Review 5.  Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.

Authors:  Debbie T Lim; Amy C Cannella; Kaleb D Michaud; Ted R Mikuls
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

6.  Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial.

Authors:  S Silverman; H N Viswanathan; Y-C Yang; A Wang; S Boonen; S Ragi-Eis; P Fardellone; N Gilchrist; P Lips; M Nevitt; S Palacios Gil-Antuñano; K Pavelka; D Revicki; J Simon; D Macarios; E S Siris
Journal:  Osteoporos Int       Date:  2011-07-19       Impact factor: 4.507

Review 7.  Fibromyalgia: from pathophysiology to therapy.

Authors:  Tobias Schmidt-Wilcke; Daniel J Clauw
Journal:  Nat Rev Rheumatol       Date:  2011-07-19       Impact factor: 20.543

8.  Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis.

Authors:  Joshua F Baker; Erica Billig; Kaleb Michaud; Said Ibrahim; Liron Caplan; Grant W Cannon; Andrew Stokes; Vikas Majithia; Ted R Mikuls
Journal:  Arthritis Rheumatol       Date:  2015-07       Impact factor: 10.995

Review 9.  The humanistic and economic burden of systemic lupus erythematosus : a systematic review.

Authors:  Rachel Meacock; Nicola Dale; Mark J Harrison
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

10.  The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2010-03-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.